| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
| Targets |
Cy5-beta-Amyloid (42-1), human targets beta-amyloid (Abeta) peptides, which are the primary components of amyloid plaques found in the brains of individuals with Alzheimer's disease. The reverse sequence (42-1) is often used to minimize aggregation while maintaining binding properties for assay development.
|
|---|---|
| ln Vitro |
As a fluorescent probe, Cy5-beta-Amyloid (42-1), human has no direct biological activity. It is used to monitor amyloid aggregation kinetics in vitro via fluorescence spectroscopy and to visualize Abeta localization and distribution in cells and tissues using fluorescence microscopy or confocal imaging. Researchers employ it to screen for inhibitors of Abeta aggregation in cell-free systems.
|
| ln Vivo |
No direct in vivo activity data are reported for Cy5-beta-Amyloid (42-1), human, as it is a fluorescent tracer. It can be injected into animal models to track the biodistribution and clearance of amyloid peptides. It may also be used in ex vivo imaging of brain sections from Alzheimer's disease model mice to quantify amyloid plaque burden.
|
| Enzyme Assay |
For binding assays, the fluorescent peptide is dissolved in PBS or Tris buffer (pH 7.4) and incubated with pre-formed Abeta aggregates or synthetic membranes. Thioflavin T (ThT) fluorescence is measured at λex=450 nm and λem=485 nm to monitor aggregation kinetics. For receptor binding, competitive displacement assays using radiolabeled Abeta peptides are performed.
|
| Cell Assay |
Cellular assays are conducted using neuronal cell lines (e.g., SH-SY5Y, PC12) or primary neurons. Cells are treated with Cy5-beta-Amyloid (42-1), human (1-10 microM) for 6-24 h. Uptake and intracellular accumulation of the labeled peptide are visualized by confocal microscopy or flow cytometry (Cy5 channel: λex=633-647 nm, λem=665-670 nm). Cytotoxicity induced by Abeta aggregates is measured by MTT or LDH assays.
|
| Animal Protocol |
For in vivo imaging, wild-type or transgenic Alzheimer‘s disease model mice (e.g., APP/PS1, 5xFAD) receive intracerebroventricular (ICV) or tail vein injection of Cy5-beta-Amyloid (42-1), human. At various time points, the animals are sacrificed, and brain sections are imaged using a fluorescence microscope or in vivo imaging system (IVIS). Alternatively, the peptide can be microinjected into specific brain regions to monitor local aggregation and clearance.
|
| ADME/Pharmacokinetics |
Cy5-beta-Amyloid (42-1), human (C2₉₆H4₆4N₈2O₈₆S1) has an approximate molecular weight of 6.7-7.0 kDa depending on the Cy5 conjugation site. The peptide is soluble in DMSO or PBS (pH 7.2-7.4) containing 0.1% BSA. The lyophilized powder should be stored at -20degC sealed and protected from light. For in vitro use, stock solutions in DMSO (1 mM) are stored at -80degC for up to 6 months. No detailed PK data are available.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for Cy5-beta-Amyloid (42-1), human beyond the general cytotoxicity associated with Abeta peptides. The compound is for research use only and not intended for human use. Standard laboratory safety precautions, including protective equipment and handling under a fume hood, should be followed when working with this fluorescent peptide.
|
| References | |
| Additional Infomation |
Cy5-beta-Amyloid (42-1), human is a research-use only fluorescent probe for studying Alzheimer‘s disease pathology. It is not a therapeutic drug and has not entered clinical trials or received regulatory approval. The reverse sequence (42-1) is often used to minimize aggregation during handling. This tool is valuable for screening anti-amyloid compounds and studying Abeta interactions with cells and tissues. Commercially available from various peptide synthesis suppliers with purity >95% (HPLC).
|
| Appearance |
Solid powder
|
|---|---|
| Synonyms |
Cy5-Amyloid β Peptide (42-1)(human)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 20 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
